Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum toxin type A - ATGC/EuBiologics

Next Previous
Drug Profile

Botulinum toxin type A - ATGC/EuBiologics

Alternative Names: ATGC-100; Clostridium Botulinum Type A - ATGC/EuBiologics

Latest Information Update: 15 Dec 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ATGC Biotech
  • Developer EuBiologics
  • Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Glabellar lines

Most Recent Events

  • 22 Mar 2021 EuBiologics completes a phase I/II trial in Glabellar lines in South Korea (NCT03970876)
  • 29 Jun 2020 Phase-III clinical trials in Glabellar lines in South Korea (Parenteral) (NCT04830345)
  • 19 Apr 2019 Phase-I/II clinical trials in Glabellar lines in South Korea (IV) (NCT03970876)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top